Sara Orndoff-Snyder, MSN

Oncology Account Executive, Pittsburgh, PA

CELL:  412.335.0449| EMAIL:

Come Chat with Sara:

Join Zoom Meeting

 Meeting ID: 708 412 0152

Password: 255485

 One tap mobile

+13017158592,,7084120152# US (Washington D.C)

+13126266799,,7084120152# US (Chicago)

 Dial by your location

        +1 301 715 8592 US (Washington D.C)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 669 900 6833 US (San Jose)

Meeting ID: 708 412 0152

Find your local number:

 Join from a Video System (Example: Cisco)

Password: 255485

 Join from a Microsoft Video System (Example: Surface Hub)

Password: 255485



Thought Leader Liaison, Hematology Franchise

CELL   614-352-8603






At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 300 clinical trials and more than 20 different tumor types. For more information, please visit



            PDF icon venclexta-ddi-brochure.pdf                        

            PDF icon venclexta-patient-initiation-checklist.pdf    

            PDF icon VENCLEXTA-Treatment-Guide_CLL.pdf   

            PDF icon VENCLEXTA-Treatment-Guide_CLL.pdf                 




Back to the Virtual Exhibit Hall